Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Background AKT pathway activation is implicated in endocrine-therapy resistance. Data on
the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …

Background In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole
resulted in significantly longer progression-free survival than letrozole alone among …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Background Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to
improve progression-free survival in women with aromatase inhibitor-resistant oestrogen …

Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …

The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …

Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival,
metabolism, and immunity. mTOR is usually assembled into several complexes such as …